Photo via Unsplash
A bioelectricity startup has secured $95 million in Series C funding to advance its neural interface technology for people living with paralysis—one of the largest funding rounds in the emerging field of brain-computer interfaces. The company’s approach combines high-density electrode arrays with sophisticated machine learning signal processing to restore communication and eventually motor function in patients with spinal cord injuries and ALS.
The Engineering Challenge of Reading the Paralyzed Brain
Neural interfaces for paralysis have shown remarkable progress in recent years. Research groups at BrainGate, Neuralink, and several academic centers have demonstrated that recordings from motor cortex neurons can be decoded to control computer cursors, robotic arms, and even the patient’s own muscles through functional electrical stimulation. But translating these research demonstrations into reliable, long-term medical devices has proved consistently challenging.
The core difficulty is biological: the brain treats implanted electrodes as foreign bodies. Over weeks and months, glial cells encapsulate the electrodes in scar tissue, increasing electrical impedance and degrading signal quality. Early-generation devices that recorded crisp neural signals in the first weeks post-implantation often became effectively deaf within a year. The startup’s new funding will support clinical trials of an implantable device using a novel electrode material—a flexible polymer composite designed to match the mechanical properties of brain tissue—that preclinical studies suggest can maintain stable recording quality for at least five years.
Signal processing is the other major challenge. Motor cortex neurons do not transmit movement commands in a simple one-to-one code. Decoding intended movements from the complex, overlapping activity of hundreds of neurons requires machine learning algorithms sophisticated enough to separate signal from noise, and adaptive enough to compensate for the inevitable drift in neural population activity that occurs as memories form, moods change, and the electrode-tissue interface ages. The company’s decoder uses a continuous recalibration approach that updates its model of neural activity patterns every few minutes, maintaining decoding accuracy without requiring the user to perform explicit calibration tasks.
From Laboratory Demonstrations to Medical Devices
The gap between academic proof-of-concept and clinical reality is where most neural interface technologies have stalled. Research systems typically require a cart full of equipment, a trained technician to operate them, and hours of daily setup. Patients with paralysis need something they can use independently, at home, throughout their waking hours.
The startup’s architecture addresses this directly. The implanted device handles all signal acquisition and preliminary processing onboard, transmitting compressed neural features wirelessly to a smartphone-sized external processor. The entire system is designed to be donned in minutes, with automatic calibration that adapts to the user’s current neural state. Battery life supports twelve hours of continuous operation—a full waking day.
Long-term, the company envisions a system that could enable paralyzed patients to control assistive technology, communicate at natural typing speeds, and potentially regain motor function through integration with peripheral nerve stimulation. When decoded motor commands are paired with electrical stimulation of the muscles those commands would normally drive, some patients with incomplete spinal cord injuries have demonstrated partial recovery of voluntary movement—a finding that suggests the interface is not merely compensating for lost function but actively engaging the nervous system’s own repair mechanisms.
The Broader Race to Restore Movement
This funding round arrives as competition in the neural interface space intensifies. Neuralink’s N1 chip, first implanted in a human in early 2024, demonstrated high-bandwidth recording from over a thousand electrode sites. Synchron’s Stentrode takes a less invasive approach, threading a mesh electrode array through blood vessels to sit against the motor cortex without penetrating brain tissue. Precision Neuroscience offers a thin-film array that can be placed through a much smaller craniotomy than traditional electrode grids.
Each approach involves trade-offs between signal quality, invasiveness, and longevity. What unites them is a shared recognition that the technical barriers to viable neural interfaces are no longer primarily scientific. The underlying neuroscience is sufficiently understood. What remains is the engineering: building devices reliable and safe enough to live inside a human brain for decades, with the clinical evidence to support regulatory approval. The $95 million will go primarily toward the pivotal trial that could make that case to the FDA.
For the patients waiting—an estimated 5.4 million Americans live with some form of paralysis—the pace of progress carries enormous personal stakes. Neural interfaces will not restore sensation, will not cure the underlying injury, will not undo what happened. But for someone who has not spoken in years, or moved a hand intentionally in a decade, the ability to type a message or operate a wheelchair independently represents a qualitative shift in what a life can contain. That is the promise this funding round is chasing.
The $95 Million in Context
Ninety-five million dollars is substantial but not unusual for a neural interface company at the Series C stage, where the transition from research to pivotal clinical trial demands the full apparatus of regulatory compliance, manufacturing scale-up, clinical site establishment, and patient recruitment infrastructure. What it signals is continued conviction from sophisticated investors—most Series C rounds in neural interfaces are led by institutional healthcare investors with deep due diligence capabilities—that the technical and biological risks in this space are manageable relative to the market opportunity. The total addressable market for communication and mobility restoration devices in paralysis is estimated in the tens of billions of dollars globally. Whether this particular company reaches it depends on the pivotal trial results, the regulatory pathway, and the reimbursement landscape—variables that $95 million buys the time to resolve, but does not determine.
The total addressable market for neural communication and mobility restoration in paralysis is estimated in the tens of billions of dollars globally. Whether this particular company reaches commercial scale depends on the pivotal trial results, the regulatory pathway, and the reimbursement landscape—variables that the Series C funding buys time to resolve. What is clear is that investor confidence in the technical and biological feasibility of neural interfaces for paralysis is higher now than at any prior point in the field’s history. The scientific consensus has shifted: the question is no longer whether useful brain-computer interfaces for paralysis are possible, but how quickly the engineering and regulatory challenges can be resolved. The $95 million is a bet that the answer is: soon enough to matter.
Sources and Further Reading
- Hochberg, L.R. et al. (2012). Reach and grasp by people with tetraplegia using a neurally controlled robotic arm. Nature, 485.
- Collinger, J.L. et al. (2013). High-performance neuroprosthetic control by an individual with tetraplegia. The Lancet, 381(9866).
- Musk, E. & Neuralink (2019). An integrated brain-machine interface platform with thousands of channels. bioRxiv.